Diabetic Kidney Disease, Type2 Diabetes
Conditions
Keywords
DKD, miRNA-25, miRNA-192
Brief summary
Diabetes kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in western countries and its incidence is worryingly increasing worldwide. Cardiovascular disease shows a continuous relationship with declining of renal function in type 2 diabetes patients. Moreover, there is a strong evidence of all-cause mortality risk excess even in patients with early stages kidney disease. MicroRNA (miRNA) are small non-coding RNA molecules, containing 21-25 nucleotides, that modulate post-transcriptional gene expressions. In the past years many human miRNAs involved in the pathogenesis of renal disease have been discovered, such as miR-192, miR-194, miR-204 and miR-25. Among these, miR-192 and miR-25, are receiving greater attention while it seems that they play a role in glomerulosclerosis and renal fibrosis. However too few data are available in large publish trials among patients with renal impairment and the role of serum and urinary levels of miR-192 and miR-25 in people with preserved renal function remain unclear. To evaluate the association between serum and urinary expression of miR-192 and miR-25 and renal function (according to different extent of renal impairment) in patients with or without type 2 diabetes.
Detailed description
The day of the study patients undergo a routine clinical evaluation. Whole blood samples are collected from an antecubital vein to assess serum/plasma aliquots of 200 μl each (frozen at -80°C until required for quantitation) for evaluation of biochemical parameters (fasting glucose, HbA1c, lipid profile, serum creatinine, uric acid, electrolytes, liver function enzymes, albumin) and determination of serum miR-192 and miR-25. Two urine samples will be also collected to assess aliquots of 200 μl each (frozen at -80°C until required for quantitation) for determination of albumin:creatinine ratio and urine expression of miR-192 and miR-25.
Interventions
OTHERno interventions required.
The study does not require any interventions.
Sponsors
University of Pisa
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
(Group 1, Diabetic patients): * age ≥ 18 years and ≤ 75 years * male or female patients with type 2 diabetes treated with life style modification only or any OAD or insulin * BMI ≥ 20 e ≤ 40 Kg/m2 * patients able to consent
Exclusion criteria
(Group 1, Diabetic patients): * personal history of current or previous cancer or chemotherapy in the past 5 years * personal history of alcohol and/or drugs abuse in the previous 3 months * pregnancy Inclusion Criteria (Group 2, Non-diabetic patients): * age ≥ 18 years and ≤ 75 years * BMI ≥ 20 e ≤ 40 Kg/m2 * patients able to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum expression of miR-192 | Each patients will be assessed at baseline. | Levels of miR-192 will be assessed on serum and will be related to glomerular filtration rate and presence or absence of albuminuria (expressed as albumine:creatinine ratio). |
| Serum expression of miR-25 | Each patients will be assessed at baseline. | Levels of miR-25 will be assessed on serum and will be related to glomerular filtration rate and presence or absence of albuminuria (expressed as albumine:creatinine ratio). |
| Urine expression of miR-192 | Each patients will be assessed at baseline. | Levels of miR-192 will be assessed on urine and will be related to glomerular filtration rate and presence or absence of albuminuria (expressed as albumine:creatinine ratio). |
| Urine expression of miR-25 | Each patients will be assessed at baseline. | Levels of miR-25 will be assessed on urine and will be related to glomerular filtration rate and presence or absence of albuminuria (expressed as albumine:creatinine ratio). |
Countries
Italy
Outcome results
None listed